These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 2565516)

  • 21. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.
    Sánchez-Ramón S; Bellón JM; Resino S; Cantó-Nogués C; Gurbindo D; Ramos JT; Muñoz-Fernández MA
    Pediatrics; 2003 Feb; 111(2):E168-75. PubMed ID: 12563091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection.
    Blaak H; Brouwer M; Ran LJ; de Wolf F; Schuitemaker H
    J Infect Dis; 1998 Mar; 177(3):600-10. PubMed ID: 9498438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type 1 (HIV-1)-infected homosexual men.
    Tang AM; Graham NM; Kirby AJ; McCall LD; Willett WC; Saah AJ
    Am J Epidemiol; 1993 Dec; 138(11):937-51. PubMed ID: 7903021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fertility parameters in men infected with human immunodeficiency virus.
    Krieger JN; Coombs RW; Collier AC; Koehler JK; Ross SO; Chaloupka K; Murphy VL; Corey L
    J Infect Dis; 1991 Sep; 164(3):464-9. PubMed ID: 1869837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury.
    Pratt RD; Shapiro JF; McKinney N; Kwok S; Spector SA
    J Infect Dis; 1995 Sep; 172(3):851-4. PubMed ID: 7658081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
    Rezza G; Galai N; Pezzotti P; Vlahov D; Graham NM; Viale P; Angarano G
    Antivir Ther; 1997 Jul; 2(3):167-74. PubMed ID: 11322271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection.
    Selwyn PA; Alcabes P; Hartel D; Buono D; Schoenbaum EE; Klein RS; Davenny K; Friedland GH
    N Engl J Med; 1992 Dec; 327(24):1697-703. PubMed ID: 1359411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-1991.
    Jacobson LP; Kirby AJ; Polk S; Phair JP; Besley DR; Saah AJ; Kingsley LA; Schrager LK
    Am J Epidemiol; 1993 Dec; 138(11):952-64. PubMed ID: 7903022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential determination of viral load and phenotype in human immunodeficiency virus type 1 infection.
    Daar ES; Chernyavskiy T; Zhao JQ; Krogstad P; Chen IS; Zack JA
    AIDS Res Hum Retroviruses; 1995 Jan; 11(1):3-9. PubMed ID: 7734193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.
    Lancet; 1994 Apr; 343(8902):871-81. PubMed ID: 7908356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS.
    Strathdee SA; Frank JW; McLaughlin J; Leblanc M; Major C; O'Shaughnessy MV; Read SE
    J Infect Dis; 1995 Nov; 172(5):1375-9. PubMed ID: 7594682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS; Phair JP; Mitsuyasu RT
    JAMA; 1994 Aug; 272(6):437-42. PubMed ID: 7913730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
    N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.
    Lancet; 2000 Apr; 355(9210):1131-7. PubMed ID: 10791375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of antiviral therapy with zidovudine: a retrospective study on HIV-positive hemophiliacs in Italy. Italian Group of Congenital Coagulopathies.
    Arcieri R; Puopolo M; Baudo F; Chiarotti F; De Rosa V; Schinaia N; Mori PG; Ghirardini A
    Haematologica; 1995; 80(1):25-30. PubMed ID: 7758987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA; Lagakos SW; Grimes JM; Stein DS; Rooney J; Meng TC; Fischl MA; Collier AC; Phair JP; Hirsch MS
    N Engl J Med; 1995 Aug; 333(7):401-7. PubMed ID: 7616988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Killing of primary CD4+ T cells by non-syncytium-inducing macrophage-tropic human immunodeficiency virus type 1.
    Yu X; McLane MF; Ratner L; O'Brien W; Collman R; Essex M; Lee TH
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):10237-41. PubMed ID: 7937869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates.
    Fenyö EM; Morfeldt-Månson L; Chiodi F; Lind B; von Gegerfelt A; Albert J; Olausson E; Asjö B
    J Virol; 1988 Nov; 62(11):4414-9. PubMed ID: 2459416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection.
    van Rij RP; Broersen S; Goudsmit J; Coutinho RA; Schuitemaker H
    AIDS; 1998 Jun; 12(9):F85-90. PubMed ID: 9662191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival and treatment of AIDS patients 1984-1993: experience of a smaller east London HIV centre.
    Hillman RJ; Beck EJ; Mandalia S; Satterthwaite H; Rogers PA; Forster GE; Goh BT
    Genitourin Med; 1997 Feb; 73(1):44-8. PubMed ID: 9155555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.